The latest price target for Calithera Biosciences (OTCEM:CALA) was reported by Ladenburg Thalmann on November 15, 2022. The analyst firm set a price target for $0.00 expecting CALA to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Calithera Biosciences (OTCEM:CALA) was provided by Ladenburg Thalmann, and Calithera Biosciences downgraded their neutral rating.

The last upgrade for Calithera Biosciences Inc happened on August 29, 2022 when HC Wainwright & Co. raised their price target to $8. HC Wainwright & Co. previously had a neutral for Calithera Biosciences Inc.

The last downgrade for Calithera Biosciences Inc happened on November 15, 2022 when Ladenburg Thalmann changed their price target from N/A to N/A for Calithera Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Calithera Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Calithera Biosciences was filed on November 15, 2022 so you should expect the next rating to be made available sometime around November 15, 2023.

While ratings are subjective and will change, the latest Calithera Biosciences (CALA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Calithera Biosciences (CALA) is trading at is $0.03, which is out of the analyst’s predicted range.